Show simple item record

dc.contributor.authorHiggins, AL
dc.contributor.authorToffoli, M
dc.contributor.authorMullin, Stephen
dc.contributor.authorLee, C-Y
dc.contributor.authorKoletsi, S
dc.contributor.authorAvenali, M
dc.contributor.authorBlandini, F
dc.contributor.authorSchapira, AHV
dc.date.accessioned2022-03-08T11:02:56Z
dc.date.available2022-03-08T11:02:56Z
dc.date.issued2021-12
dc.identifier.issn1758-2032
dc.identifier.issn1758-2032
dc.identifier.urihttp://hdl.handle.net/10026.1/18914
dc.description.abstract

<jats:p> Mutations in GBA which are causative of Gaucher disease in their biallelic form, are the most common genetic risk factor for Parkinson's disease (PD). The diagnosis of PD relies upon clinically defined motor features which appear after irreversible neurodegeneration. Prodromal symptoms of PD may provide a means to predict latent pathology, years before the onset of motor features. Previous work has reported prodromal features of PD in GBA mutation carriers, however this has been insufficiently sensitive to identify those that will develop PD. The Remote Assessment of Parkinsonism Supporting Ongoing Development of Interventions in Gaucher Disease (RAPSODI GD) study assesses a large cohort of GBA mutation carriers, to aid development of procedures for earlier diagnosis of PD. </jats:p>

dc.format.extent451-458
dc.format.mediumPrint-Electronic
dc.languageen
dc.language.isoen
dc.publisherFuture Science Group
dc.subjectGBA
dc.subjectGaucher disease
dc.subjectParkinson's disease
dc.subjectglucocerebrosidase
dc.subjectparkinsonism
dc.subjectprodromal symptoms
dc.subjectGaucher Disease
dc.subjectGlucosylceramidase
dc.subjectHumans
dc.subjectMutation
dc.subjectParkinson Disease
dc.subjectParkinsonian Disorders
dc.subjectProdromal Symptoms
dc.titleThe remote assessment of parkinsonism supporting the ongoing development of interventions in Gaucher disease
dc.typejournal-article
dc.typeJournal Article
dc.typeResearch Support, Non-U.S. Gov't
plymouth.author-urlhttps://www.ncbi.nlm.nih.gov/pubmed/34666501
plymouth.issue6
plymouth.volume11
plymouth.publication-statusPublished
plymouth.journalNeurodegenerative Disease Management
dc.identifier.doi10.2217/nmt-2021-0032
plymouth.organisational-group/Plymouth
plymouth.organisational-group/Plymouth/Faculty of Health
plymouth.organisational-group/Plymouth/Faculty of Health/Peninsula Medical School
plymouth.organisational-group/Plymouth/REF 2021 Researchers by UoA
plymouth.organisational-group/Plymouth/REF 2021 Researchers by UoA/UoA01 Clinical Medicine
plymouth.organisational-group/Plymouth/Research Groups
plymouth.organisational-group/Plymouth/Research Groups/FoH - Applied Parkinson's Research
plymouth.organisational-group/Plymouth/Research Groups/FoH - Community and Primary Care
plymouth.organisational-group/Plymouth/Users by role
plymouth.organisational-group/Plymouth/Users by role/Academics
plymouth.organisational-group/Plymouth/Users by role/Researchers in ResearchFish submission
dc.publisher.placeEngland
dcterms.dateAccepted2021-09-30
dc.rights.embargodate2022-3-9
dc.identifier.eissn1758-2032
dc.rights.embargoperiodNot known
rioxxterms.versionofrecord10.2217/nmt-2021-0032
rioxxterms.licenseref.urihttp://www.rioxx.net/licenses/all-rights-reserved
rioxxterms.licenseref.startdate2021-12
rioxxterms.typeJournal Article/Review


Files in this item

Thumbnail
Thumbnail

This item appears in the following Collection(s)

Show simple item record


All items in PEARL are protected by copyright law.
Author manuscripts deposited to comply with open access mandates are made available in accordance with publisher policies. Please cite only the published version using the details provided on the item record or document. In the absence of an open licence (e.g. Creative Commons), permissions for further reuse of content should be sought from the publisher or author.
Theme by 
Atmire NV